利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1622 条记录 (耗时 0.048 秒)

    METHODS FOR PURIFYING PROANTHOCYANIDIN OLIGOMERS
    32.
    发明授权
    METHODS FOR PURIFYING PROANTHOCYANIDIN OLIGOMERS 有权
    程序对原花青素清洁低聚物

    公开(公告)号：EP1180516B1

    公开(公告)日：2006-08-23

    申请号：EP00906694.5

    申请日：2000-03-03

    申请人： KYOWA HAKKO KOGYO CO., LTD. ,  THE NIKKA WHISKY DISTILLING CO., LTD.

    发明人： HONDA, Shinkichi, H.O. Kyowa Hakko Kogyo Co., Ltd. ,  TAKAHASHI, Tomoya, c/oTsukuba Research Lab. ,  KAMIMURA, Ayako, c/o Tsukuba Research Lab. ,  MATSUOKA, Takako ,  KANDA, Tomomasa ,  YANAGIDA, Akio ,  HIEDA, Kazuo

    IPC分类号： C07D311/62

    CPC分类号： C07D311/62 ,  C07D311/60

    摘要： The present invention relates to a process for purifying dimeric to pentameric proanthocyanidin oligomers which comprises extracting the proanthocyanidin oligomers from raw materials containing the proanthocyanidin oligomers or crude purification products therefrom by solid-liquid extraction using methyl acetate as a liquid phase; a process for purifying dimeric to pentameric proanthocyanidin oligomers which comprises pretreating with an enzyme for hydrolysis raw materials containing the proanthocyanidin oligomers, crude purification products therefrom, or a solution containing one of these; and a process for purifying dimeric to pentameric proanthocyanidin oligomers with a uniform polymerization degree which comprises separating and purifying the proanthocyanidin oligomers by polymerization degree from raw materials containing the proanthocyanidin oligomers or crude purification products therefrom by normal phase silica gel liquid chromatography using as a mobile phase a single solvent or a mixed solvent of two or more solvents selected from the group consisting of an ester solvent, a ketone solvent, a hydrocarbon solvent, an ether solvent and an alcohol solvent.

    RECOMBINANT ANTIBODY AGAINST HUMAN INSULIN-LIKE GROWTH FACTOR
    34.
    发明公开
    RECOMBINANT ANTIBODY AGAINST HUMAN INSULIN-LIKE GROWTH FACTOR 有权
    抗生素抗体激素GEGEN人胰岛素样生长因子

    公开(公告)号：EP1676862A1

    公开(公告)日：2006-07-05

    申请号：EP04773541.0

    申请日：2004-09-24

    申请人： KYOWA HAKKO KOGYO CO., LTD.

    发明人： SHITARA, Kenya, c/o BioFrontier Laboratories ,  NAKAMURA, Kazuyasu, c/o BioFrontier Laboratories ,  OHKI, Yuji, c/o BioFrontier Laboratories

    IPC分类号： C07K16/26 ,  C12N15/13 ,  C12N1/21 ,  C12N1/19 ,  C12N1/15 ,  C12N5/10 ,  C12P21/08 ,  A61K39/395 ,  A61P3/10 ,  A61P5/06 ,  A61P35/00 ,  G01N33/15 ,  G01N33/50

    CPC分类号： C07K16/2896 ,  C07K2317/73

    摘要： It is demanded that pharmaceutical agents for therapeutic treatment of diseases such as cancer, acromegaly and diabetic complications, of which IGF is involved in the progress of the conditions.
    The present invention provides a recombinant antibody or an antibody fragment thereof which specifically binds to human insulin-like growth factor-I (hereinafter referred to as hIGF-I) and human insulin-like growth factor-II (hereinafter referred to as hIGF-II) to inhibit the biological activities of human IGF-I and human IGF-II, a transformant producing the antibody or the antibody fragment thereof, a process for producing the antibody or the antibody fragment thereof, and a medicament comprising the antibody or the antibody fragment thereof as the active ingredient therein.

    摘要翻译： 需要用于治疗癌症，肢端肥大症和糖尿病并发症等疾病的药剂，其中IGF参与病情进展。 本发明提供与人胰岛素样生长因子-I（以下称为hIGF-1）和人胰岛素样生长因子-II特异性结合的重组抗体或其抗体片段（以下称为hIGF-II ）以抑制人IGF-I和人IGF-II的生物活性，产生抗体或其抗体片段的转化体，制备抗体或其抗体片段的方法，以及包含抗体或抗体片段的药物 作为其中的活性成分。

    Alpha-1,3-fucosyltransferase
    37.
    发明授权
    Alpha-1,3-fucosyltransferase 失效
    α-1,3-岩藻糖基

    公开(公告)号：EP0643132B1

    公开(公告)日：2006-05-31

    申请号：EP94910547.2

    申请日：1994-03-28

    申请人： KYOWA HAKKO KOGYO CO., LTD.

    发明人： SASAKI, Katsutoshi ,  KURATA, Kazumi ,  HANAI, Nobuo ,  NISHI, Tatsunari

    IPC分类号： C12N9/10

    CPC分类号： C12N9/1051

    摘要： A novel alpha -1,3-fucosyltransferase which is expressed by the gene cloned from animal cells; a cDNA coding for the transferase; a method of detecting alpha -1,3-fucosyltransferase using the cDNA and inhibiting the production of the transferase; a recombinant vector containing the cDNA integrated thereinto; a cell containing the vector; and processes for producing the above. The alpha -1,3-fucosyltransferase invented is useful for producing physiologically active sugar chains, such as sialylated Lewis X, and modifications thereof.

    RNA CAPABLE OF INHIBITING EXPRESSION OF KLF5 GENE
    39.
    发明公开
    RNA CAPABLE OF INHIBITING EXPRESSION OF KLF5 GENE 审中-公开
    ZUR HEMMUNG DER EXPRESSION DES KLF5-GENSFÄHIGERNA

    公开(公告)号：EP1652917A1

    公开(公告)日：2006-05-03

    申请号：EP04771250.0

    申请日：2004-07-29

    申请人： KYOWA HAKKO KOGYO CO., LTD. ,  Nagai, Ryozo ,  Manabe, Ichiro

    发明人： NAGAI, Ryozo ,  MANABE, Ichiro ,  ISHIHARA, Atsushi c/p Pharmaceutical res center ,  TOTTORI, Tsuneaki

    IPC分类号： C12N15/09 ,  C12Q1/02 ,  A61K48/00 ,  A61P9/10 ,  A61P35/00

    CPC分类号： C12N15/113 ,  A61K38/00 ,  A61K48/00 ,  C12N2310/111 ,  C12N2310/14

    摘要： An RNA capable of suppressing the expression of KLF5 gene, which comprises a sequence consisting of 15 to 30 contiguous nucleotides of KLF5 mRNA and a sequence complementary to the sequence, and which has been designed from the nucleotide sequence of Kruppel-like factor 5 (KLF5) cDNA. Specifically, a double-stranded RNA having a strand of a sequence shown in any one of SEQ ID NOS: 2 to 16 and a strand of a sequence complementary to the sequence, in which 2 uridylic acids are added to the 3'-terminus of each of the strands. By transfecting the RNA or a vector for expression of the RNA into cells, the expression of KLF5 gene in the cells can be suppressed. The RNA or a vector for expression of the RNA can be used as a therapeutic agent for cardiovascular disease or cancer.

    摘要翻译： 能够抑制KLF5基因表达的RNA，其包含由KLF5 mRNA的15〜30个连续核苷酸和与该序列互补的序列组成的序列，并且由Kruppel样因子5（KLF5）的核苷酸序列设计 ）cDNA。 具体地说，具有SEQ ID NO：2〜16中任一项所示的序列的链的双链RNA和与序列互补的序列的链，其中2个尿苷酸加入到 每个股。 通过将RNA或用于将RNA表达的载体转染到细胞中，可以抑制细胞中KLF5基因的表达。 用于表达RNA的RNA或载体可用作心血管疾病或癌症的治疗剂。